Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Childhood Acute Lymphoblastic Leukemia
Brief Summary: The purpose of this study is to reduce the side-effects and discomfort of anti-leukemia therapy, to attain long-term control of the disease and to hopefully eradicate it.


Options:
A: Arm Label: Ancillary-Correlative (laboratory biomarker analysis); Type: N/A; Interventions: Other: Assessment of Therapy Complications, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Other: Questionnaire Administration | Intervention Type: OTHER; Name: Assessment of Therapy Complications; Assigned to Arm(s): Ancillary-Correlative (laboratory biomarker analysis) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Ancillary-Correlative (laboratory biomarker analysis) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Ancillary-Correlative (laboratory biomarker analysis) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Ancillary-Correlative (laboratory biomarker analysis)
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Biological: filgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: prednisone, Drug: vincristine sulfate, Radiation: radiation therapy | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Biological: filgrastim, Drug: cyclophosphamide, Drug: dexrazoxane hydrochloride, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: prednisone, Drug: vincristine sulfate, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: dexrazoxane hydrochloride; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm 1, Arm 2
C: Intervention Type: DRUG; Name: asparaginase (E. Coli); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: asparaginase (Erwina); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: dexrazoxane; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: cranial radiation (once daily fractionation); Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: cranial radiation (twice-daily fractionation); Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Intrathecal chemotherapy without radiation; Assigned to Arm(s): N/A
D: Arm Label: Cancer survivors; Type: N/A; Interventions: N/A | Arm Label: Sibling Controls; Type: N/A; Interventions: N/A

Answer: C